Mallinckrodt Plc.

26.03.2019 – 15:30
Mallinckrodt Announces 2019 Investigator Award for Pioneering Efforts in ECP Immunomodulation
EUR50,000 award goes to Newcastle University, in collaboration with Medical University, Graz and Newcastle Hospitals NHS Foundation Trust Staines-Upon-Thames, England (ots/PRNewswire) - Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today announced the recipient of 2019's Advancing Extracorporeal Photopheresis (ECP) Immunomodulation ...
mehr
20.03.2018 – 09:02
Mallinckrodt Announces First Investigator Award for Pioneering Efforts in ECP Immunomodulation
Staines-Upon-Thames, England (ots/PRNewswire) - EUR50,000 award goes to Rotherham NHS Foundation Trust Department of Haematology Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today announced the inaugural recipient of its Advancing Extracorporeal Photopheresis (ECP) Immunomodulation Investigator Award. The winning entry was submitted by ...
mehr